Neurosense Therapeutics Ltd. (NRSN) has released an update.
NeuroSense Therapeutics VP of R&D, Dr. Shiran Zimri, will present new findings on ALS treatment at the upcoming ALS Drug Development Summit, highlighting the progress of their PrimeC therapy. Recent results from the PARADIGM trial showed a promising 43% slowing of disease progression in high-risk ALS patients. The company is set to discuss future plans and regulatory strategies for PrimeC, aiming to address the unmet medical needs of neurodegenerative diseases.
For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.
